F-18 fluorodeoxyglucose uptake in leiomyomatous uterus.

Abstract

Leiomyomas of uterus are common disease in gynecology. It is important to differentiate leiomyoma from leiomyosarcoma at the decision of treatment methods, especially in the case of the conservative treatment for uterine leiomyoma. But the exact diagnosis of benign leiomyoma is often difficult due to the degeneration of myoma by imaging modalities including magnetic resonance imaging. Recently, whole-body positron emission tomography (PET) using F-18 fluorodeoxyglucose (FDG) has been used for a diagnosis of malignant tumors. There is a growing body of evidence for the use of FDG in differentiating malignant from benign disease. But optimal utilization in gynecology remains unclear. Our case represents increased uptake of FDG in myomatous uterus, which is pathologically confirmed benign leiomyoma by the hysterectomy. Immunohistochemical analysis of glucose transporter-1 showed positive in endometrial tissue and negative in leiomyoma. Our case indicates that myomatous uterus in premenopausal women shows the potential pitfall of a positive result of FDG-PET.

• Authors: M Shida, M Murakami, H Tsukada, Y Ishiguro, K Kikuchi, E Yamashita, H Kajiwara, M Yasuda, M Ide
• Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (Int J Gynecol Cancer) 2007 Jan-Feb Vol. 17 Issue 1 Pg. 285-90 ISSN: 1048-891X [Print] England
• PMID: 17291269 (Publication Type: Case Reports, Journal Article)

Chemical References

• Fluorine Radioisotopes
• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Female
• Fluorine Radioisotopes
• Fluorodeoxyglucose F18 (pharmacokinetics)
• Humans
• Leiomyoma (diagnostic imaging, metabolism)
• Middle Aged
• Radionuclide Imaging
• Radiopharmaceuticals (pharmacokinetics)
• Uterine Neoplasms (diagnostic imaging, metabolism)